Back

Effects of aliskiren on mortality, cardiovascular outcomes and adverse events in diabetics with cardiovascular disease or risk: a systematic review and meta-analysis of 13,395 patients

27 August 2017 (15:35 - 16:25)
Organised by:
Congress Presentation Part of: Diabetes mellitus: from "omics to complications" Diabetes, dysglycaemia and metabolic syndrome ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Sean Zheng

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)

6 More presentations in this session

Presentation thumbnail
Use of insulin providers versus insulin sensitizers and risk of out-of-hospital cardiac arrest - a nationwide case-time-control study
Mr G. Hognason Mohr (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
Once daily low-dose aspirin reduces urinary thromboxane B2 effectively even at 12-24 hours from dosing in the ASCEND (A Study of Cardiovascular Events iN Diabetes) trial
Doctor T. Aung (Oxford, GB)
Abstract Slides
Presentation thumbnail
Detailed description of myocardial infarctions and the various subtypes in the LEADER trial
Professor M. Nauck (Bochum, DE)
Abstract Slides
Presentation thumbnail
Diabetes risk assessment of cardiovascular free individuals, through the calculation and evaluation of a lifestyle index; results of the 10-year follow up of the ATTICA study.
Professor D. Panagiotakos (Athens, GR)
Abstract Slides
Presentation thumbnail
Genome-wide DNA methylation analysis for type 2 diabetes mellitus and cardiovascular disease: from a 23-Year follow-up in the Da Qing Diabetes Prevention Study

Access the full session

Session thumbnail
Diabetes mellitus: from "omics to complications"

The Event

Event poster

ESC Congress 2017

27 August 2017 15:35 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources